Aclarion (ACON) Set to Post Quarterly Earnings on Wednesday

Aclarion (NASDAQ:ACON) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Aclarion to announce earnings of ($1.15) per share and revenue of $0.03 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 12:30 PM ET.

Aclarion (NASDAQ:ACON) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($0.07). The business had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. Aclarion had a negative return on equity of 59.34% and a negative net margin of 10,948.81%. On average, analysts expect Aclarion to post ($4.51) EPS for the current fiscal year and ($5.37) EPS for the next fiscal year.

Aclarion Price Performance

Aclarion stock opened at $1.76 on Wednesday. The company has a market capitalization of $5.07 million, a price-to-earnings ratio of -0.24 and a beta of 1.21. Aclarion has a one year low of $1.71 and a one year high of $9.36. The company’s fifty day moving average price is $2.29 and its two-hundred day moving average price is $2.84.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research report on Tuesday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $7.50.

Insider Transactions at Aclarion

In related news, Director Ryan Bond purchased 21,122 shares of the stock in a transaction on Thursday, August 13th. The shares were bought at an average price of $2.37 per share, for a total transaction of $50,059.14. Following the completion of the acquisition, the director directly owned 76,122 shares in the company, valued at approximately $180,409.14. This trade represents a 38.40% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders purchased a total of 51,863 shares of company stock worth $125,670 over the last three months. 0.01% of the stock is owned by corporate insiders.

About Aclarion

Aclarion, Inc is a medical technology company focused on improving the diagnosis and treatment of chronic low back pain. The company develops data-driven tools intended to help physicians identify the spinal discs most likely to be contributing to a patient’s pain and support more informed treatment decisions.

Its principal product is Nociscan, a cloud-based software platform that analyzes magnetic resonance spectroscopy data from the spine. Using proprietary algorithms and chemical biomarkers associated with disc degeneration, Nociscan is designed to provide information about disc health and help distinguish potentially painful discs from discs that may not be the primary source of symptoms.

Aclarion’s technology is intended for use by spine specialists, radiologists and other healthcare providers as an adjunct to conventional imaging and clinical evaluation.